Product
CD22-CAR
1 clinical trial
10 indications
Indication
Non-Hodgkin lymphomaIndication
Large Cell LymphomaIndication
Follicular LymphomaIndication
Acute lymphoblastic leukemiaIndication
B-ALLIndication
B-precursor acute lymphoblastic leukemiaIndication
Acute Lymphoblastic LeukemiaIndication
Acute Lymphocytic LeukemiaIndication
Non-Hodgkin LymphomaIndication
B-cell Non-Hodgkin LymphomaClinical trial
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2019-04-03